Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debasish Sundi

Showing results (51-60 of 75) with videos related to

Pageof 8
Sort By:
Oncoimmunology|May 10, 2019
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activationDevin Plote, Woonyoung Choi, Sharada Mokkapati, et al.
Iscience|July 26, 2022
Sex-biased adaptive immune regulation in cancer development and therapyJohanna M Schafer, Tong Xiao, Hyunwoo Kwon, et al.
European Urology|October 8, 2015
Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor LocationFarzana A Faisal, Debasish Sundi, Jeffrey J Tosoian, et al.
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
BJU International|January 18, 2019
Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?Chad A Reichard, Yaw A Nyame, Debasish Sundi, et al.
BJU International|April 16, 2014
Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk featureFarzana A Faisal, Debasish Sundi, Phillip M Pierorazio, et al.
European Urology|March 8, 2020
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-GuérinRoger Li, Debasish Sundi, Jingsong Zhang, et al.
Cancer|March 15, 2021
Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomyLamont J Wilkins, Jeffrey J Tosoian, Chad A Reichard, et al.
European Urology Oncology|December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant ChemotherapyPetros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
European Urology|August 2, 2016
Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical ProstatectomyJeffrey J Tosoian, Fawaz Almutairi, Carlos L Morais, et al.
Pageof 8

Showing results (51-60 of 75) with videos related to

Sort By:
Pageof 8
Oncoimmunology|May 10, 2019
Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activationDevin Plote, Woonyoung Choi, Sharada Mokkapati, et al.
Iscience|July 26, 2022
Sex-biased adaptive immune regulation in cancer development and therapyJohanna M Schafer, Tong Xiao, Hyunwoo Kwon, et al.
European Urology|October 8, 2015
Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor LocationFarzana A Faisal, Debasish Sundi, Jeffrey J Tosoian, et al.
European Urology|April 30, 2015
Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk MenAshley E Ross, Kasra Yousefi, Elai Davicioni, et al.
BJU International|January 18, 2019
Does time from diagnosis to treatment of high- or very-high-risk prostate cancer affect outcome?Chad A Reichard, Yaw A Nyame, Debasish Sundi, et al.
BJU International|April 16, 2014
Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk featureFarzana A Faisal, Debasish Sundi, Phillip M Pierorazio, et al.
European Urology|March 8, 2020
Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-GuérinRoger Li, Debasish Sundi, Jingsong Zhang, et al.
Cancer|March 15, 2021
Oncologic outcomes among Black and White men with grade group 4 or 5 (Gleason score 8-10) prostate cancer treated primarily by radical prostatectomyLamont J Wilkins, Jeffrey J Tosoian, Chad A Reichard, et al.
European Urology Oncology|December 28, 2023
PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant ChemotherapyPetros Grivas, Vadim S Koshkin, Xiangying Chu, et al.
European Urology|August 2, 2016
Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical ProstatectomyJeffrey J Tosoian, Fawaz Almutairi, Carlos L Morais, et al.
Pageof 8